Literature DB >> 2949787

Cyclosporine A treatment in four cases of aplastic anemia.

A Porwit, P Panayotides, E Mansson, E Osby, R Hast, P Reizenstein.   

Abstract

Cyclosporine A (CyA) treatment of 4 patients with severe aplastic anemia, who were ineligible for bone marrow transplantation, was carried out for periods of between 12 weeks to 20 months. A normalization of Hb and bone marrow, together with a marked improvement in WBC and platelet counts, were observed in only one of these four patients. The remission was maintained for 20 months under continuous treatment. A relapse occurred only when the patient himself interrupted treatment. No serious side effects were observed with CyA doses of 4-10 mg/kg/daily and blood concentrations of 200-400 ng/ml. No significant changes in T helper/T suppressor ratios were noted during the course of CyA treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2949787     DOI: 10.1007/bf00321033

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  29 in total

1.  Cyclosporine in refractory severe aplastic anemia.

Authors:  F Wisløff; H C Godal
Journal:  N Engl J Med       Date:  1985-05-02       Impact factor: 91.245

2.  Effect of activated lymphocytes on the regulation of hematopoiesis: suppression of in vitro granulopoiesis by OKT8+Ia+T cells induced by alloantigen stimulation.

Authors:  S Nakao; M Harada; K Kondo; K Odaka; M Ueda; K Matsue; T Mori; K Hattori
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

3.  Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial.

Authors:  R Champlin; W Ho; R P Gale
Journal:  N Engl J Med       Date:  1983-01-20       Impact factor: 91.245

Review 4.  Immunosuppressive treatment of aplastic anemia as an alternative treatment for bone marrow transplantation.

Authors:  E Gluckman; A Marmont; B Speck; E C Gordon-Smith
Journal:  Semin Hematol       Date:  1984-01       Impact factor: 3.851

5.  Cyclosporine in refractory severe aplastic anemia.

Authors:  P A Stryckmans; J P Dumont; T Velu; L Debusscher
Journal:  N Engl J Med       Date:  1984-03-08       Impact factor: 91.245

6.  Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo.

Authors:  N C Zoumbos; P Gascon; J Y Djeu; N S Young
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

7.  Suppression of erythroid-colony formation by lymphocytes from patients with aplastic anemia.

Authors:  R Hoffman; E D Zanjani; J D Lutton; R Zalusky; L R Wasserman
Journal:  N Engl J Med       Date:  1977-01-06       Impact factor: 91.245

8.  In vitro tests for distinguishing possible immune-mediated aplastic anemia from transfusion-induced sensitization.

Authors:  B J Torok-Storb; C Sieff; R Storb; J Adamson; E D Thomas
Journal:  Blood       Date:  1980-02       Impact factor: 22.113

9.  Immune suppression of hematopoiesis in aplastic anemia: activity of T-gamma lymphocytes.

Authors:  A Bacigalupo; M Podestà; M C Mingari; L Moretta; M T Van Lint; A Marmont
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

10.  Generation of CFU-c suppressor T cells. VI. Effect of cyclosporin A.

Authors:  M Podestà; A Bacigalupo; F Frassoni; M R Raffo; G Piaggio; M Repetto; M T Van Lint; A Marmont
Journal:  Acta Haematol       Date:  1983       Impact factor: 2.195

View more
  1 in total

Review 1.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.